By Jacqueline Bell (February 19, 2008, 12:00 AM EST) -- Alexion Pharmaceuticals Inc. has agreed to pay $10 million to the Oklahoma Medical Research Foundation to settle a patent dispute related to the drug Soliris.
Under the settlement, Alexion will pay $10 million in order to acquire all rights and interests to the patents at issue, making payments over the remainder of 2008 and 2009. The ongoing litigation will be dismissed.
Alexion's Soliris drug was approved by the FDA to treat a rare blood disorder, paroxysmal nocturnal humoglobinuria, or PNH, which strikes one in a million people and can lead to disability and a premature death.
The drug does not cure...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!